Introduction {#s1}
============

Several previous studies have shown that subjects with higher uric acid (UA) levels more frequently have LV hypertrophy [@pone.0082735-Krishnan1], [@pone.0082735-Mitsuhashi1], [@pone.0082735-Matsumura1]. Serum UA is affected or linked to various factors that may also be associated with LV hypertrophy, including obesity, hypertension, insulin resistance, and chronic kidney disease [@pone.0082735-Iwashima1], [@pone.0082735-Woodiwiss1], [@pone.0082735-Taddei1], [@pone.0082735-Vernooij1]. The finding that UA level was associated with LV hypertrophy detected by echocardiography independent of renal function, blood pressure, or impaired glucose metabolism [@pone.0082735-Viazzi1], [@pone.0082735-Yoshitomi1], although there may be certain gender differences, suggests that the association between UA and LV hypertrophy may not merely be circumstantial.

Parathyroid hormone (PTH), a hormone secreted from parathyroid glands, raises plasma calcium levels by increasing absorption, reducing excretion, and promoting release of calcium from bones; in turn, PTH is regulated by the calcium concentration in the plasma. Besides its effect on calcium homeostasis, serum PTH may have an impact on the development of cardiovascular events [@pone.0082735-Pilz1] and may cause an increase in cardiac mass among the elderly community-dwelling population [@pone.0082735-vanBallegooijen1], although studies on whether PTH is associated with cardiac abnormalities, either directly or indirectly via other factors, have not been conclusive [@pone.0082735-Fujii1], [@pone.0082735-Walker1]. The findings that hyperuricemia and gout occurred with increased frequency among patients with hyperparathyroidism [@pone.0082735-Hui1] and that serum UA was positively associated with serum PTH in community-dwelling older men [@pone.0082735-Hui1], [@pone.0082735-Nabipour1] suggest that there is a relationship between serum UA and PTH. Such an association may be further supported by the observations that recombinant PTH may induce hyperuricemia [@pone.0082735-Saag1] and parathyroidectomy reduces serum uric acid levels [@pone.0082735-Broulik1].

Nevertheless, to the best of our knowledge it seems that whether the relationship between serum UA and cardiac hypertrophy, when present, is dependent or independent of serum PTH has not been examined. To this end, we have herein investigated, among cardiac patients, whether the association between UA and LV hypertrophy is dependent on serum PTH levels and other calcium-phosphate metabolism-related parameters, including serum fibroblast growth factor-23 (FGF23), which has also been shown to have a link with cardiac hypertrophy [@pone.0082735-Faul1], [@pone.0082735-Shibata1].

Methods {#s2}
=======

Ethics {#s2a}
------

The current retrospective study was approved by the Ethics Committee of Osaka Medical College. The study included only subjects who provided written informed consent for whom sufficient information regarding the data analysis was available.

Study Population {#s2b}
----------------

Between 2012 January and 2012 December, 138 male cardiac inpatients for whom sufficient clinical and echocardiographic information was available were enrolled in the current study. Among the 138 patients, 21 patients and one patient were taking xanthine oxidase inhibitor (allopurinol) and uricosuric drugs, respectively, and were subsequently excluded. As a result, 116 patients, mean age 65±12 years, were included in the current study.

Laboratory Analysis {#s2c}
-------------------

Blood samples were collected in the morning after an overnight fast. Aliquots of serum and plasma were obtained and stored at -80 degrees immediately until use. Ca, IP, C-reactive protein (CRP), and B-type natriuretic peptide (BNP) were measured by routine laboratory methods. When serum albumin was 4 mg/dL or lower, serum Ca levels were corrected by using the formula: Ca+(4--"serum albumin"), and designated as corrected Ca (cCa). Serum levels of intact PTH (iPTH) and 25(OH)D were measured using electrochemiluminescence and a competitive protein binding assay (Mitsubishi Medience, Tokyo, Japan). Serum levels of intact FGF23 were measured using a two-step FGF23 enzyme immunoassay (ELISA) kit (Kainos Laboratories Inc., Tokyo, Japan) according to the manufacturer's instructions. Measurement of FGF23 was performed by two experienced researchers in the institute: the interclass correlation coefficient (ICC) of intra- and inter-operator reliability for FGF23 was 0.98 and 0.95, respectively. The eGFR was calculated by the following Modification of Diet in Renal Disease equation modified for Japanese subjects: eGFR  =  194×(serum creatinine)^−1.094^×(age)^−0.287^ [@pone.0082735-Matsuo1]. Among parameters related to calcium-phosphate metabolism, 25(OH)D levels were available for 114 patients (98%).

Echocardiography {#s2d}
----------------

Echocardiographic examinations were performed with a Vivid 7 Dimension equipped with a multi-frequency transducer (GE Healthcare, Vingmed, Norway). Left ventricular end-diastolic dimension (LVDd), interventricular septal thickness (IVST) and posterior wall thickness (PWT) were measured at end diastole. For calculation of the LV mass (LVM), we used the formula proposed by Devereux et al. [@pone.0082735-Devereux1] modified as follows: 0.8×1.04×\[(LVDd+IVST+PWT)^3^-LVDd^3^\]+0.6 [@pone.0082735-Wachtell1]. Body surface area (BSA) was calculated using the following formula: (body weight)^0.425^×(height)^0.725^×0.007184. The LVM index (LVMI) was then calculated as the ratio of LVM to BSA. When the LVMI was greater than 118 g/m^2^, LV hypertrophy was defined to be present [@pone.0082735-Roman1].

Patients were divided into the following 4 groups according to their LVMI and the relative wall thickness (RWT), which was calculated as PWT×2/LVDd with a partition value of 0.44 [@pone.0082735-Savage1]: (i) normal geometry, normal RWT and LVMI; (ii) concentric remodeling, increased RWT and normal LVMI; (iii) eccentric hypertrophy, normal RWT and LV hypertrophy; and (iv) concentric hypertrophy, LV hypertrophy and RWT [@pone.0082735-Koren1].

The LV ejection fraction (LVEF) was calculated either by modified Simpson's method using the apical 4-chamber view, designated LVEF-Simpson, or by the Teichholz' formula, designated LVEF-Teichholz [@pone.0082735-Teichholz1]. LVEF-Simpson data were available for 103 patients (89%). The ratio of the peak velocity of early filling (E) to the early peak diastolic mitral annulus velocity obtained at the septal and lateral annulus (e') was measured using pulsed wave tissue Doppler imaging. Among the116 study, patients 92 (79%) had sinus rhythm, 17 (15%) had atrial fibrillation rhythm, and the remaining 7 (6%) had pacemaker rhythm. The value of E/e', which was used as an index for diastolic LV function for patients with sinus rhythm, was available for 51 patients (55%) of the 92 patients with sinus rhythm.

Statistical Analysis {#s2e}
--------------------

Baseline characteristics were assessed with standard descriptive statistics. Data were expressed as either mean ± standard deviation or median and interquartile range. A Spearman rank correlation test was used to assess the correlation between two variables. For multivariate analysis, multivariate linear regression and multivariate logistic regression analyses were used to examine the relationship with, respectively, LVMI and LV hypertrophy. Log-transformed FGF23 (log\[FGF23\]) and intact PTH (log\[iPTH\]) were confirmed to be normally distributed by the Kolmogorov-Smirnov test. Data analysis was performed by IBM SPSS statistics version 21.0 (SPSS, Chicago, IL). A value of P\<0.05 was taken to be statistically significant.

Results {#s3}
=======

Patient Characteristics {#s3a}
-----------------------

Among the 138 male patients, the median UA level was 5.9 mg/dL. Neither age nor body mass index differed significantly among the four UA quartile groups ([Table 1](#pone-0082735-t001){ref-type="table"}). Ischemic heart disease (IHD) was the most common cardiovascular condition (75/116, 65%). Eighty seven (75%) patients were taking at least one of the following medications: angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, beta adrenergic blocker, or calcium channel blockers; the prevalence of taking medication did not significantly differ among the UA quartile groups. Treatment with loop diuretics was more prevalent in the higher UA quartiles. Twenty four patients (21%) were taking diuretics that may affect serum UA (loop and/or thiazide diuretics); one patient was taking both classes of diuretic. Among 40 patients (34%) diagnosed to have diabetes, 29 were being treated with anti-diabetic medications, and the remaining 11 were diagnosed by their patient history and/or laboratory findings. Because oral glucose challenge test is not included as a routine examination on admission, however, the prevalence of diabetes may have been underestimated.

10.1371/journal.pone.0082735.t001

###### Demographic characteristics of the study patients.

![](pone.0082735.t001){#pone-0082735-t001-1}

                                      First UA quartile   Second UA quartile   Third UA quartile   Fourth UA quartile  
  ---------------------------------- ------------------- -------------------- ------------------- -------------------- ---------
  Uric acid, median (range) mg/dL      4.3 (2.8--4.9 )      5.3 (5.0--5.8)      6.2 (5.9--6.8)      7.6 (6.9--11.0)     \<0.001
  Age, years                              64.4±12.6           66.6±13.3            64.4±11.2           64.7±11.3         0.871
  Body mass index, kg/m^2^                23.4±2.9             23.4±2.9            23.4±3.0             23.3±4.1         0.776
  Systolic blood pressure, mmHg            129±19               129±20              129±19               125±18          0.646
  Pulse rate, bpm                           73±14               70±11                73±13               76±25           0.500
  Past History                                                                                                         
  previous PCI                            15 (53.6)           11 (36.7)            14 (48.3)            10(34.5)         0.399
  previous CABG                            2 (7.1)             4 (13.3)             0 (0.0)             1 (3.4)          0.166
  Cardiovascular                                                                                                       
  Ischemic heart disease, n (%)           21 (75.0)           19 (63.3)            18 (62.1)            17(58.6)         0.597
  Arrhythmic disease, n (%)               6 (21.4)             7 (23.3)            8 (27.6)             4 (13.8)         0.634
  Cardiomyopathy, n (%)                    2 (7.1)             1 (3.3)             3 (10.3)             1 (3.4)          0.628
  NYHA class III/IV, n (%)                 1 (3.6)             1 (3.3)             4 (13.8)             6 (20.7)         0.082
  Aortic aneurysm, n (%)                   1 (3.6)             3 (10.0)             0 (0.0)             3 (10.3)         0.268
  Peripheral artery disease, n (%)         1 (3.6)             6 (20.0)             2 (6.9)             1 (3.4)          0.074
  Valvular heart disease, n (%)            0 (0.0)             1 (3.3)             4 (13.8)             3 (10.3)         0.148
  Cardiac rhythm                                                                                                       
  Sinus rhythm, n (%)                     22 (78.6)           24 (80.0)            23 (79.3)           23 (79.3)         0.996
  Atrial fibrillation, n (%)              5 (17.9)             4 (13.3)            4 (13.8)             4 (13.8)       
  Pace maker rhythm, n (%)                 1 (3.6)             2 (6.7)              2 (6.9)             2 (6.9)        
  Smoking status                                                                                                       
  Never, n (%)                            5 (17.9)             5 (16.7)            7 (24.1)             4 (13.8)         0.912
  Former, n (%)                           18 (64.3)           20 (66.7)            15 (51.7)           19 (65.5)       
  Current, n (%)                          5 (17.9)             5 (16.7)            7 (24.1)             6 (20.7)       
  Medication                                                                                                           
  ACE inhibitors/ARB, n (%)               14 (50.0)           13 (43.3)            18 (62.1)           18 (62.1)         0.380
  Beta blockers, n (%)                    7 (25.0)             6 (20.0)            16 (55.2)           14 (48.3)         0.011
  Calcium channel blockers, n (%)         10 (35.7)           11 (36.7)            14 (48.3)           13 (44.8)         0.716
  Sulfonylurea, n (%)                     6 (21.4)             2 (6.7)             3 (10.3)             4 (13.8)         0.387
  DPP4 inhibitors, n (%)                  3 (10.7)             2 (6.7)             4 (13.8)             1 (3.4)          0.518
  Insulin, n (%)                           1 (3.6)             3 (10.0)             1 (3.4)             2 (6.9)          0.680
  Statin, n (%)                           13 (46.4)           16 (53.3)            14 (48.3)           11 (37.9)         0.693
  Fibrate, n (%)                           0 (0.0)             0 (0.0)              1 (3.4)             0 (0.0)          0.388
  Loop diuretics, n (%)                   3 (10.7)             1 (3.3)             5 (17.2)            12 (41.4)         0.001
  Thiazide diuretics, n (%)                0 (0.0)             0 (0.0)             3 (10.3)             1 (3.4)          0.102
  Aldosterone antagonist, n (%)            2 (7.1)             0 (0.0)              2 (6.9)             5 (17.2)         0.102

UA, uric acid; PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blockers; DPP4, dipeptidyl peptidase-4.

Serum UA and Laboratory and Echocardiographic Parameters {#s3b}
--------------------------------------------------------

Laboratory and echocardiographic data were compared across the UA quartile groups by the Kruskal-Wallis test ([Table 2](#pone-0082735-t002){ref-type="table"}). Serum creatinine increased in accordance with the UA value. Among the parameters related to calcium-phosphate metabolism, intact PTH was highest among patients in the top UA quartiles. LVMI was higher in the third and fourth UA quartile; on the other hand, RWT did not significantly differ among the groups ([Table 2](#pone-0082735-t002){ref-type="table"}). The correlation coefficient between LVEF-Simpson and LVEF-Teichholz was 0.564 (P\<0.001). Either LVEF-Simpson or LVEF-Teichholz differed significantly between the groups. LVEF-Teichholz was significantly smaller in the highest UA quartile than in the lower three UA quartiles (P = 0.029). We did not regard this as a true difference, however, because (i) such a relationship was not observed when LVEF-Simpson was used instead, and (ii) LVEF determined by the Teichholz' formula may be less accurate when applied to a population that includes subjects who have abnormal regional LV wall motion, such as the current study population. E/e' in the patients with sinus rhythm was not different among UA quartile groups.

10.1371/journal.pone.0082735.t002

###### Laboratory and echocardiographic data.

![](pone.0082735.t002){#pone-0082735-t002-2}

                                       First UA quartile   Second UA quartile   Third UA quartile   Fourth UA quartile  
  ----------------------------------- ------------------- -------------------- ------------------- -------------------- -------
  White blood cell count, x10^3^/µL    5.58(4.49--6.58)    5.51 (4.98--6.78)    6.27 (4.89--7.15)   6.12 (4.95--7.41)    0.440
  Hemoglobin, g/dL                     14.3 (12.9--15.0)   13.8 (12.8--14.9)    14.5 (13.2--15.3)   13.4 (12.2--14.4)    0.103
  Platelet count, x10^4^/µL            19.7 (16.8--22.5)   22.3 (17.0--25.5)    21.0 (16.6--25.3)   21.4 (19.2--25.1)    0.563
  Total protein, g/dL                   6.8 (6.5--7.3)       7.1 (6.9--7.3)      6.8 (6.4--7.2)       6.9 (6.8--7.2)     0.146
  Albumin, g/dL                         4.1 (3.8--4.3)       4.1 (3.8--4.3)      3.9 (3.7--4.2)       3.9 (3.7--4.1)     0.301
  Alanine aminotransferase, IU/L       19.5 (16.0--29.5)   24.0 (13.8--43.0)    20.0 (15.0--28.5)   18.0 (15.0--30.0)    0.764
  Blood urea nitrogen, mg/dL              16 (14--18)         16 (13--17)          16 (12--19)         18 (14--22)       0.103
  Serum creatinine, mg/dL              0.82 (0.69--0.95)   0.86 (0.75--0.97)    0.90 (0.78--1.03)   0.98 (0.82--1.27)    0.013
  eGFR, mL/min/1.73 m^2^               52.1 (43.4--66.6)   50.3 (42.7--63.7)    47.8 (41.2--56.3)   48.0 (32.8--54.4)    0.078
  C-reactive protein, mg/dL            0.08 (0.02--0.15)   0.12 (0.03--0.40)    0.05 (0.03--0.23)   0.07 (0.04--0.47)    0.547
  B-type natriuretic peptide, pg/mL    23.4 (10.3--74.6)   27.6 (14.6--55.0)    22.7 (9.9--51.3)     66.9 (18.7--231)    0.120
  Corrected calcium, mg/dL              9.2 (8.8--9.3)       9.0 (8.8--9.3)      9.0 (8.8--9.2)       9.2 (9.1--9.4)     0.183
  Inorganic phosphate, mg/dL            3.2 (2.8--3.6)       3.3 (2.9--3.8)      3.3 (2.9--3.7)       3.4 (3.0--3.8)     0.602
                                       31.0(24.3--42.0)    36.5 (30.0--43.3)      (24.5--48.5)         33.5--59.0)      
  FGF23, pg/mL                         49.7 (33.5--80.1)    71.9 (48.0--136)    54.7 (28.8--73.9)    66.6 (45.1--86)     0.097
  25(OH) vitamin D, pg/mL (n = 114)    24.9 (17.1--31.9)    19.4 (16.2--23)     20.3 (16.0--25.3)    20.1 (18.3--25)     0.152
  Echocardiographic data                                                                                                
  LVDd, mm                              4.9 (4.5--5.3)       4.8 (4.5--5.3)      4.8 (4.7--5.3)       5.4 (4.9--6.1)     0.036
  LVDs, mm                              3.1 (2.9--3.6)       3.0 (2.7--3.5)      3.2 (2.9--3.7)       3.5 (3.0--4.7)     0.054
  IVST, mm                              0.9 (0.9--1.0)       1.0 (0.9--1.1)      1.0 (0.9--1.1)       1.0 (0.9--1.1)     0.267
  PWT, mm                               1.0 (0.9--1.0)       1.0 (0.9--1.1)      1.0 (0.9--1.1)       1.0 (0.8--1.1)     0.523
  LV mass index, g/m^2^                  100 (83--109)        98 (81--124)        100 (88--116)       123 (92--154)      0.022
  Relative wall thickness              0.41 (0.35--0.43)   0.39 (0.35--0.48)    0.41 (0.36--0.44)   0.37 (0.30--0.45)    0.544
  LVEF-Simpson, % (n = 103)               59 (51--64)         62 (54--65)          60 (56--64)         60 (41--66)       0.870
  LVEF-Teichholz, %                       65 (56--70)         63 (59--73)          62 (58--69)         59 (44--68)       0.176
  Left atrial dimension, mm             4.0 (3.2--4.5)       3.8 (3.3--4.1)      3.9 (3.6--4.5)       4.0 (3.6--4.5)     0.400
  E/e\' (n = 51)                        8.9 (6.4--10.3)     7.8 (6.2--10.4)      8.1 (6.5--10.7)     10.8 (8.0--13.0)    0.314
   Left ventricular geometry                                                                                            
    Normal                                 20 (71.4)           15 (50.0)            19 (65.5)            9 (31.0)        0.022
    Concentric remodeling, n (%)           5 (17.9)             6 (20.0)            3 (10.3)             3 (10.3)       
    Eccentric hypertrophy, n (%)           3 (10.7)             5 (16.7)            4 (13.8)            12 (41.4)       
    Concentric hypertrophy, n (%)           0 (0.0)             4 (13.3)            3 (10.3)             5 (17.2)       

LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic dimension; IVST, interventricular septal thickness; PWT, posterior wall thickness; LVEF, left ventricular ejection fraction.

By Spearman's rank correlation test, serum creatinine, intact PTH, BNP, and LVMI were positively, and eGFR was negatively, associated with serum UA ([Table 3](#pone-0082735-t003){ref-type="table"}). LVEF-Teichholz, but not LVEF-Simpson, showed a significant correlation with serum UA. Serum UA was correlated significantly with LVMI in 75 patients with ischemic heart disease (R = 0.261, P = 0.024) and in 41 patients without (R = 0.327, P = 0.037). Serum UA was correlated with LVMI significantly in 40 patients with diabetes (R = 0.398, P = 0.011) and in 76 patients without diabetes (R = 0.253, P = 0.028).

10.1371/journal.pone.0082735.t003

###### Spearman's correlation coefficients for the association with serum UA.

![](pone.0082735.t003){#pone-0082735-t003-3}

                                         R      P value
  ----------------------------------- -------- ---------
  Age                                  --0.13    0.169
  Body mass index                      --0.02    0.854
  Systolic blood pressure              --0.01    0.896
  Serum creatinine                      0.27     0.003
  eGFR                                 --0.20    0.028
  B-type natriuretic peptide            0.18     0.047
  Corrected calcium                     0.04     0.680
  Inorganic phosphate                   0.09     0.335
  Intact parathyroid hormone            0.34    \<0.001
  FGF23                                 0.07     0.482
  25(OH) vitamin D, pg/mL (n = 114)    --0.10    0.298
  LV mass index, g/m^2^                 0.30     0.001
  Relative wall thickness              --0.16    0.092
  LVEF-Simpson, % (n = 103)            --0.03    0.752
  LVEF-Teichholz, %                    --0.21    0.022
  Left atrial dimension, mm             0.14     0.130
  E/e\' (n = 51)                        0.15     0.279

LVEF, left ventricular ejection fraction.

Multivariate Analysis {#s3c}
---------------------

Multivariate linear regression model showed that serum UA was significantly associated with LVMI after adjustment for age ([Table 4](#pone-0082735-t004){ref-type="table"}, model 1), and this association remained significant after further adjustment for blood pressure and eGFR (model 2), and serum calcium-phosphate metabolism-related parameters (cCa, IP, intact PTH, and FGF23) (model 3). The strength of the association was not attenuated when model 3 was applied to patients who were not taking either loop or thiazide diuretics; however, this model was not significant (P\>0.05) when applied to patients taking these diuretics. We did not include 25(OH)D in the model because it did not have a significant correlation with UA ([Table 3](#pone-0082735-t003){ref-type="table"}) or with LVMI by univariate analysis (standardized β = 0.071, P = 0.455).

10.1371/journal.pone.0082735.t004

###### Multivariate linear regression analysis examining the association between various parameters and left ventricular mass index.
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                             Model 1   Model 2   Model 3   Diuretics (-)   Diuretics (+)                                                                
  ------------------------- --------- --------- --------- --------------- --------------- --------- -------- -- ------- -------- -- ------- -------- -- -------
  log(UA)                     0.35               \<0.001       0.35                        \<0.001    0.24       0.011    0.28       0.006   --0.07      0.817
  Age                         0.21                0.018        0.18                         0.072     0.16       0.083    0.14       0.156    0.45       0.202
  Systolic blood pressure      \-                  \-          0.15                         0.098     0.18       0.039    0.32       0.001    0.18       0.468
  eGFR                         \-                  \-          0.01                         0.906     0.06       0.554    0.08       0.445    0.48       0.096
  log(cCa)                     \-                  \-           \-                           \-      --0.03      0.713    0.08       0.411   --0.26      0.224
  log(IP)                      \-                  \-           \-                           \-       0.19       0.031    0.23       0.020    0.29       0.238
  log(iPTH)                    \-                  \-           \-                           \-       0.25       0.008    0.23       0.024    0.16       0.440
  log(FGF23)                   \-                  \-           \-                           \-       0.14       0.114   --0.01      0.954    0.48       0.061

β, the standardized correlation coefficient. Diuretics indicate medication with loop and/or thiazide diuretics. Std

Next, we analyzed the association of age, high blood pressure (systolic blood pressure≥140 mmHg and/or diastolic blood pressure≥90 mmHg), chronic kidney disease (eGFR\<60 mL/min.1.73 m^2^), UA, intact PTH, and FGF23 with LV hypertrophy by multivariate logistic regression analysis. We included FGF23 in this model because we previously found a significant association between FGF23 and LVMI in cardiac patients [@pone.0082735-Shibata1]. Log(UA) was found to be significantly associated with LV hypertrophy with an odds ratio of 2.79 (95% CI 1.47-5.28, per 1 SD increase) in the whole study population, and with an odds ratio of 4.42 (95% CI 1.66-11.77, per 1 SD increase) in patients who were not taking either loop or thiazide diuretics ([Figure 1](#pone-0082735-g001){ref-type="fig"}). Next, eccentric LV hypertrophy or concentric LV hypertrophy was used as a dependent variable in place of LVMI in a model using the same independent variables. Log(UA) was significantly associated with eccentric LV hypertrophy with an odds ratio of 2.51 (95% CI 1.27-4.94, per 1 SD increase, P = 0.008), but in this model, the association between log(UA) and concentric LV hypertrophy did not reach statistical significance (odds ratio 1.72 \[95% CI 0.74-4.01\], per 1 SD increase, P = 0.206).

![Multivariate logistic regression analysis using left ventricular (LV) hypertrophy as the independent variable.\
Odds ratios for age, log-transformed uric acid (log\[UA\]), intact parathyroid hormone (log\[iPTH\]), and FGF23 (log\[FGF23\]) were calculated on the basis of an increase in a one standard deviation (SD) for each variable. A. Whole study population (n = 116). B. Patients who were not taking loop and/or thiazide diuretics (n =  92). High blood pressure indicates systolic blood pressure≥140 mmHg and/or diastolic blood pressure≥90 mmHg, and chronic kidney disease indicates eGFR\<60 mL/min.1.73 m^2^.](pone.0082735.g001){#pone-0082735-g001}

Discussion {#s4}
==========

In the current study, we investigated whether the relationship between serum UA and LV hypertrophy, if present at all, is independent of serum intact PTH, which may be associated with serum UA. In fact, intact PTH was significantly correlated with UA with a correlation coefficient of 0.335 (P\<0.001). Both UA and intact PTH were associated with LV hypertrophy by univariate analysis. The association between serum UA and LVMI, and that between serum UA and LV hypertrophy were shown to be independent of serum intact PTH and other possible confounders, including age, blood pressure, renal function (eGFR), by linear regression and logistic regression analyses, respectively.

To date, several studies have investigated the association between serum UA and LV hypertrophy. It is also important to determine whether the observed association, if present, is dependent or independent of other possible confounding variables because higher serum UA levels may be associated with hypertension, renal dysfunction, diabetes, conditions which are also related to LV hypertrophy [@pone.0082735-AgabitiRosei1], [@pone.0082735-Eguchi1]. For example, in an analysis of 3305 essentially healthy male individuals, Mitsuhashi et al. showed that individuals with UA values of 6.6--11.0 mg/dL had an increased prevalence of LV hypertrophy, which was independent of age, body mass index, serum creatinine, hypertension, diabetes and hyperlipidemia [@pone.0082735-Mitsuhashi1]. In that study, unlike in the current one, electrocardiographic criteria were used for the determination of LV hypertrophy. In addition, Viazzi et al. demonstrated that the association between serum UA and cardiac hypertrophy remained significant after adjustment for body mass index, age, creatinine clearance, and high-density lipoprotein cholesterol in middle-aged untreated female patients with essential hypertension [@pone.0082735-Viazzi1]. In the Framingham Offspring Cohort, Krishnan et al. also found a significant association between serum UA and LV wall thickening, however, the observed association lost statistical significance after multivariate adjustment [@pone.0082735-Krishnan1]. Little seems to be known about the mechanism, if there is one, by which UA induces myocardial hypertrophy; possibilities may include activation of the renin-angiotensin system, enhanced production of reactive oxygen species, and upregulation of endothlin-1 expression [@pone.0082735-Yu1], [@pone.0082735-Chen1].

Similar to the case of serum UA, the relationship between PTH and LV hypertrophy has been examined in several previous studies. Fujii et al. reported that a relationship between intact PTH and LV hypertrophy in patients with chronic dialysis may be observed only when intact PTH levels are extremely high [@pone.0082735-Fujii1]. On the other hand, higher PTH concentrations were associated with greater LV mass in an older-aged community-dwelling cohort [@pone.0082735-vanBallegooijen1], and plasma PTH was an independent predictor of LV hypertrophy in patients undergoing chronic hemodialysis [@pone.0082735-Randon1]. We also found that serum intact PTH was positively associated with LV hypertrophy among cardiac patients [@pone.0082735-Shibata1]. PTH may induce hypertrophy of cardiomyocytes via activating MAPK pathway [@pone.0082735-Liu1].

Several studies have described the association between serum UA and PTH. Serum UA levels were significantly correlated with intact PTH levels among patients with primary hyperparathyroidism [@pone.0082735-Valdemarsson1]. In addition, serum UA levels were associated with serum calcium, PTH, and 25(OH)D after adjusting for potential confounders among community-dwelling elderly men [@pone.0082735-Nabipour1]. The finding that parathyroidectomy reduced serum UA [@pone.0082735-Ishay1] may be explained by the fact that PTH modulates serum UA mainly through changes in uric acid clearance [@pone.0082735-Yoneda1]. On the other hand, to the best of our knowledge, no studies have examined whether the relationship observed between serum UA and LV hypertrophy is dependent or independent of PTH.

In the current study, we showed that serum UA was associated with LV hypertrophy independently of PTH levels and other possible confounders, including age, high blood pressure chronic kidney disease, and FGF23 level, in cardiac patients. In this study population, PTH also showed a positive and independent association with LV mass. The observed relationship observed between UA and LV hypertrophy is not likely to be due to diuretic medications, which can affect serum UA levels, for patients with cardiac hypertrophy and heart failure, because the association between serum UA and LV hypertrophy was observed among patients who were not taking loop and/or thiazide diuretics. Due to the small number of the subjects who were taking aldosterone antagonists, we did not assess whether such drugs would modify the relationship between serum UA and LV hypertrophy. Along with the measurement of renin or aldosterone concentrations, this point should be examined in future studies, as it was recently suggested that activation of mineralocorticoid receptor and secretion of PTH may mutually affected [@pone.0082735-Tomaschitz1].

It was found that serum UA was significantly associated with eccentric, but no concentric, LV hypertrophy; however, these assessments should be repeated among a higher number of study patients. We also found that serum UA was not associated with LVEF determined by modified Simpson's method. Whether patients with hitgher serum UA are more susceptible to LV hypertrophy than systolic dysfunction awaits evaluation in future studies.

Several attempts have recently been made to evaluate whether reduction of UA will lead to an improvement in cardiac abnormalities. For example, Rekharaj et al. demonstrated that allopurinol regressed LV hypertrophy and improved endothelial function in patients with ischemic heart disease [@pone.0082735-Rekhraj1], and Szwejkowski et al. showed that allopurinol regressed LV mass in diabetic patients [@pone.0082735-Szwejkowski1]. Our findings provide additional information on whether or not modulation of serum UA will lead to the amelioration of cardiac geometrical abnormalities.

There are several limitations in the current study. First, we enrolled cardiac inpatients with a wide variety of cardiac abnormalities; therefore, whether UA represents an independent risk factor for LV hypertrophy in patients with a specific condition―hypertrophic cardiomyopathy, for example―requires further investigation. Second, we excluded patients who were taking UA lowering agents. Whether the association between serum UA and LV hypertrophy might be modified by certain UA lowering drugs should be assessed in future studies.

In summary, among male cardiac patients, serum UA was associated with LV hypertrophy independent of intact PTH levels, which showed a significant correlation with serum UA, and other possible confounders, including blood pressure and renal function. Whether strategies leading to UA lowering would improve cardiac performance by decreasing LV mass in cardiology patients awaits further investigation.
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